Program For Tapinarof News Today

- Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxis - Tapinarof was well-tolerated

- Two posters will present data across secondary efficacy outcomes, quality of life and tolerability scores of tapinarof cream 1% once daily - Dermavant Sciences, a clinical-stage biopharmaceutical

Patients from PSOARING 3 who completed the survey preferred tapinarof to prior topical treatments with 81.7% considering it more effective Dermavant Sciences, a clinical-stage biopharmaceutical company

- Patient satisfaction results from tapinarof long-term extension study for the treatment of plaque psoriasis in adults to be presented - Dermavant Sciences, a clinical-stage biopharmaceutical company

(0) - Approximately One in Five Tapinarof Patients Achieved At Least 90% Disease Clearance - - A Significantly Higher Portion of Psoriasis Patients Experienced Clinically Meaningful Improvements in Itch with Tapinarof Compared to Vehicle - - Improvements in DLQI Exceeded MCID at Week 12 with Statistical Significance Compared to Vehicle - - Data Will Be Included in NDA Submission for Tapinarof, Expected Mid-2021 - Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to develo...

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021 Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavants two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting Experienc...

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data from Dermavants PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upc...